##semicolon##
poliangiitli granulematoz, rinosinusit, biokimyoviy markerlar, C-reaktiv oqsil, mochevina, kreatinin, umumiy oqsil, ANCA, tizimli shikastlanish##submission.citations##
Hunter RW, Welsh N, Farrah TE, Gallacher PJ. ANCA-associated vasculitis. BMJ. 2020;369:m 1070.
King C, Harper L. Small vessel vasculitides: an update. Autoimmun Rev. 2024;23(8):103429.
Delvino P, La Rocca G, et al. Systemic vasculitis: one year in review 2025. Clin Exp Rheumatol. 2025;43(Suppl.).
Watts RA, Hatemi G, Burns JC, et al. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022; 18:155–172.
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30–47.
KDIGO ANCA Vasculitis Work Group. KDIGO 2024 clinical practice guideline for the management of ANCA-associated vasculitis. Kidney Int. 2024;105(3S):S71–S116.
Horai Y, Fujimoto S, Amano K, et al. Current diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. J Clin Med. 2025 ;14(5):1724.
Geetha D, Dua A, Yue H, et al. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomized trial. Ann Rheum Dis. 2024;83(2):223–232.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021; 384:599–609.
Puéchal X. Update on targeted treatments for ANCA-associated vasculitis. Joint Bone Spine. 2025;92(3):105458.
Garlapati P, Li J. Granulomatosis with Polyangiitis. StatPearls [Internet]. StatPearls Publishing; 2024.
Potentas-Policewicz M, Fijolek J. Granulomatosis with polyangiitis: clinical characteristics and outcome of patients treated in a tertiary referral centre. Front Med (Lausanne). 2024;11.
Wadström K, Börjesson O, Moshtaghi-Svensson J, et al. Incidence and prevalence of granulomatosis with polyangiitis in Sweden, 2006–2019: a register-based study. Semin Arthritis Rheum. 2025.
Alberici F, Fredi M, Tomelleri A, et al. Treatment goals in ANCA-associated vasculitis: defining remission and beyond. Front Immunol. 2024; 15:1409129.